1. Home
  2. LYEL vs ADCT Comparison

LYEL vs ADCT Comparison

Compare LYEL & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lyell Immunopharma Inc.

LYEL

Lyell Immunopharma Inc.

HOLD

Current Price

$23.70

Market Cap

490.1M

Sector

Health Care

ML Signal

HOLD

Logo ADC Therapeutics SA

ADCT

ADC Therapeutics SA

HOLD

Current Price

$4.38

Market Cap

484.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LYEL
ADCT
Founded
2018
2011
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
490.1M
484.4M
IPO Year
2021
2019

Fundamental Metrics

Financial Performance
Metric
LYEL
ADCT
Price
$23.70
$4.38
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
4
Target Price
$30.60
$7.75
AVG Volume (30 Days)
74.3K
741.8K
Earning Date
05-12-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
30.86
EPS
N/A
N/A
Revenue
$36,000.00
$81,357,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$16,285.34
$66.49
P/E Ratio
N/A
N/A
Revenue Growth
N/A
14.85
52 Week Low
$0.39
$1.20
52 Week High
$45.00
$4.98

Technical Indicators

Market Signals
Indicator
LYEL
ADCT
Relative Strength Index (RSI) 55.08 64.25
Support Level $21.27 $3.28
Resistance Level $27.30 $4.77
Average True Range (ATR) 1.71 0.27
MACD 0.43 0.07
Stochastic Oscillator 74.68 67.28

Price Performance

Historical Comparison
LYEL
ADCT

About LYEL Lyell Immunopharma Inc.

Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Share on Social Networks: